at Nasdaq.com (Jan 23, 2015)
Acorda Therapeutics (ACOR) says a proof-of-concept trial shows AMPYRA, the company's FDA approved walking treatment for multiple sclerosis, also improves walking in patients with post-stroke deficits. ACOR says once it has completed its analysis it will consult with the FDA on developing the drug for use by stroke survivors. Shares +8.6% premarket.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs